#15,953
Citing substantial improvements in their pandemic situation, the UK government will begin to allow greater visitation to care homes and has announced further easing of COVID restrictions starting May 17th.
The picture painted by last night's release from the UK's SAGE (Scientific Advisory Group for Emergencies) on COVID, however, is somewhat less sanguine.
They report a `significant increase' in the B.1.617.2 variant (including community transmission), and warn that SARS-CoV-2 continues to evolve antigenically, which may negatively impact vaccine effectiveness down the road.
They state that:
- it is `. . . highly likely that there will be a further resurgence in hospitalisations and deaths at some point . . . ';
- and that "Eventually it is likely that the virus will display substantial antigenic variation and current vaccines may fail to protect against transmission, infection, or even against disease caused by newer variants."
The recent arrival and rapid spread of the B.1.617.2 variant - which considering the dire anecdotal reports from India, has the potential to be highly disruptive - appears to be behind much of the caution being expressed.
But SAGE also warns that other problematic variants may emerge down the road.
Eighty-eighth SAGE meeting on COVID-19, 5 May 2021.
Held via Video Teleconference.
Summary
1. There has been a significant recent increase in prevalence of the B.1.617.2 variant, including some community transmission. PHE is currently prioritising case finding and containment for this variant. Early indications, including from international experience, are that this variant may be more transmissible than the B.1.1.7 variant (low confidence).
2. SARS-CoV-2 is continuing to evolve antigenically (high confidence). There is a need for medium and long-term strategies for vaccination in response to this. Effective vaccine updates will require coordinated virus and immunity surveillance, linked to serology, immunology, structural biology, and viral phenotyping. The UK should build on what it has developed during the pandemic to create a sustainable hub for this.
3. Modelling shows that taking step 3 of the roadmap is alone highly unlikely to put unsustainable pressure on the NHS. It is, however, likely to lead to R being greater than 1 in England, and therefore an increase in infections. The full impact of step 3 on hospitalisations and deaths will not be seen until mid-June at the earliest.
4. It remains highly likely that there will be a further resurgence in hospitalisations and deaths at some point, however, the scale, shape, and timing remain highly uncertain.
5. The resurgence will be smaller if baseline measures and sustained changes in behaviour which reduce transmission are maintained beyond the end of the roadmap (high confidence). The speed of vaccine rollout is also a key factor in the size of the resurgence (high confidence). The 2 biggest risks (absent new variants) are that either high contact patterns emerge early, or there is low vaccine rollout amongst younger adults. The combination of these 2 would lead to a larger resurgence.
6. A variant which either substantially escapes immunity or is highly transmissible (more so than B.1.1.7) could lead to a very significant wave of infections, potentially larger than that seen in January 2021 if there were no interventions. Given the uncertainty around the properties of any such variant the modelling is based on some illustrative scenarios only. Maintaining control of transmission of any such variants will be more difficult when there are fewer measures in place. Reducing the number of variant infections should be a priority for policy.
7. There remain several sources of uncertainty in the modelling, including around behavioural responses to changes in policy (after both step 3 and step 4), the impact of any seasonal variation in transmission, the extent of waning immunity, vaccine rollout speed, and the impact of vaccination on transmission (including from asymptomatic infected people).
Situation update
8. SPI-M estimates that there are between 1,000 and 5,000 new infections per day in England.
9. R is estimated to be between 0.8 and 1.0 in England, between 0.7 and 1.0 for both Scotland and Wales, and between 0.8 and 1.1 for Northern Ireland. Current estimates do not yet fully reflect recent changes, such as the return of schools after Easter holidays, but will reflect behavioural changes since the easing of restrictions in England on 12 April 2021.
10. At a local level, estimates of R for most areas from one analysis have increased over the last fortnight, but in most cases remain below 1 (though there are local areas in all nations where the epidemic is increasing). If there is a small overall increase in transmission nationally (for example due to relaxation of restrictions), R would go above 1 in many more areas. In these cases, local outbreaks could coalesce and lead to regional transmission. As SAGE has advised previously, dealing with outbreaks quickly will be important.
11. Comparing CoMix time-series data with infections and hospitalisations shows that in the past increases in contacts have been followed by increases in R, infections, and hospitalisations. In 2020 the number of contacts remained low until the start of August, despite there being many policy changes over that period. There has been a recent increase in the number of adult contacts, but this remains lower than that seen last August and is increasing more slowly. Contact survey data and mobility data will continue to be useful lead indicators.
12. There has been a significant recent increase in prevalence of the B.1.617.2 variant, including some community transmission. PHE is currently prioritising case finding and containment for this variant. Early indications, including from international experience, are that this variant may be more transmissible than the B.1.1.7 variant (low confidence). One hypothesis is that this is linked to the P681R mutation.
13. Sequencing all cases from hospital patients remains important for surveillance and understanding of the impact of variants.
14. Confirming positive lateral flow test results with PCR tests is important, in part because it allows samples to be obtained for sequencing.
Actions
- COG-UK, NHSE and NHSTT to consider potential options to increase proportion of samples from hospitals which are sequenced
- PHE to continue to prioritise control of variants and policymakers to factor risk into policy choices
- Vaccine updates and efficacy against new variants
15. SARS-CoV-2 is evolving antigenically (high confidence). Some variants are less well neutralised by antibodies raised to current vaccines, and the vaccine efficacy against these variants is lower than for the existing predominant virus. There is therefore a need for medium and long-term strategies for vaccination.
16. Administration of further doses of current vaccines, which are based on the spike protein from the Wuhan-like virus that emerged in 2019, might maintain and or boost protection into winter 2021 and 2022, but potentially less so for individuals with a less robust immune response, and less so if substantially antigenically variant viruses circulate widely.
17. Eventually it is likely that the virus will display substantial antigenic variation and current vaccines may fail to protect against transmission, infection, or even against disease caused by newer variants. Updating the vaccine to keep pace with viral evolution or searching for more broadly protective vaccines are potential solutions to this.
18. There are some things which can be learnt from the approach to updating influenza vaccines, including the potential to account for prior immunity in optimising vaccine choice. However, there will be differences between SARS-CoV-2 and influenza, and so not all of the findings from the latter will necessarily be applicable.
19. Effective vaccine updates will require coordinated virus and immunity surveillance, which has been a strength of the UK so far, but this will also need to be linked to serology, immunology, structural biology, and viral phenotyping. The UK should build on what it has developed during the pandemic to create a sustainable hub for this.
Actions
- UKHSA to work with Wendy Barclay, Derek Smith and other relevant groups to outline the requirements for academic input into the system for surveillance and vaccine update; a sustainable structure is required
In early December, with the first COVID vaccines ready to roll out, it appeared as if we were nearing the end of a long, dark tunnel. The discovery of not one - but several - new COVID variants of concern (B.1.1.7, B.1.351 & P.1) has proven to be a serious setback, as have the huge variant fueled outbreaks in Brazil and India.
While there is still much we don't know about the B.1.617.x variant - what we have seen suggests it might be another major hurdle to overcome in this pandemic, and so there is a natural reluctance to declare victory prematurely.
Regardless of what we want, do, or say . . . the virus continues to dictate the terms of this pandemic. The best we can hope to do is respond appropriately.
